Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?

Appreciation of the immune effects of targeted agents has grown, and efforts to combine these agents with immunotherapy are underway to enhance therapeutic responses. Multiple ongoing trials are examining this concept; however, nuances exist with regard to timing, sequence, and combinatorial strategies. Clin Cancer Res; 23(2); 327–9. ©2016 AACR. See related article by Deniger et al., p. 351

[1]  S. Rosenberg,et al.  A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma , 2016, Clinical Cancer Research.

[2]  F. Hodi,et al.  Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma , 2016, Journal of Immunotherapy for Cancer.

[3]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[4]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[5]  J. Wargo,et al.  Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma , 2014, Oncoimmunology.

[6]  S. Rosenberg,et al.  Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.

[7]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[8]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[9]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[11]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.